Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Zealand Pharma (ZLDPF) vs. Competitors

201 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
ZLDPFZealand Pharma$35.93$2.34B5.45-55.37%Moderate BuyUnlock the ZLDPF analyst price target with TipRanks PremiumZLDPFUnlock the ZLDPF top-analyst price target with TipRanks Premium
RDHLRedHill Biopharma$0.36$3.20M-0.36-66.36%―Unlock the RDHL analyst price target with TipRanks PremiumZLDPF vs RDHLUnlock the RDHL top-analyst price target with TipRanks Premium
VSTMVerastem$7.70$970.31M-4.251.92%Strong BuyUnlock the VSTM analyst price target with TipRanks PremiumZLDPF vs VSTMUnlock the VSTM top-analyst price target with TipRanks Premium
MNKDMannKind$3.96$1.27B-16.75-21.84%Strong BuyUnlock the MNKD analyst price target with TipRanks PremiumZLDPF vs MNKDUnlock the MNKD top-analyst price target with TipRanks Premium
OTLKOutlook Therapeutics$0.40$96.41M-0.36-74.78%Moderate BuyUnlock the OTLK analyst price target with TipRanks PremiumZLDPF vs OTLKUnlock the OTLK top-analyst price target with TipRanks Premium
BMYBristol-Myers Squibb$62.93$128.63B13.9434.90%Moderate BuyUnlock the BMY analyst price target with TipRanks PremiumZLDPF vs BMYUnlock the BMY top-analyst price target with TipRanks Premium
PFEPfizer$28.86$164.50B40.8615.16%HoldUnlock the PFE analyst price target with TipRanks PremiumZLDPF vs PFEUnlock the PFE top-analyst price target with TipRanks Premium

Performance Comparison

-100%-75%-50%-25%0%25%50%75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
ZLDPFZealand Pharma35.93-43.57-54.81%
RDHLRedHill Biopharma0.36-0.68-65.38%
VSTMVerastem7.70-1.45-15.85%
MNKDMannKind3.96-1.03-20.58%
OTLKOutlook Therapeutics0.40-1.37-77.63%
BMYBristol-Myers Squibb62.9318.1240.42%
PFEPfizer28.865.3622.78%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts